Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$28.30 USD

28.30
37,883,682

-0.22 (-0.77%)

Updated Oct 31, 2024 04:00 PM ET

After-Market: $28.34 +0.04 (0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (53 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Gilead (GILD) Drug Gets FDA Nod for Non-Hospitalized COVID Patients

by Zacks Equity Research

Gilead (GILD) gets FDA approval for label expansion of Veklury for the treatment of non-hospitalized patients at high risk for COVID-19 disease progression.

AbbVie's (ABBV) Skyrizi Gets FDA Nod for Psoriatic Arthritis

by Zacks Equity Research

AbbVie (ABBV) secures approval in the United States for Skyrizi to treat adult patients with active psoriatic arthritis.

Best Growth Stocks to Buy for January 24th

by Zacks Equity Research

WLK, PFE, and M made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 24, 2022

Nuvation (NUVB) Gets FDA Clearance for Oncology Candidate

by Zacks Equity Research

Nuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination with Lynparza or Xtandi in multiple tumor types following IND clearance by the FDA.

Kinjel Shah headshot

Pharma Stock Roundup: GSK's Consumer Unit Offer Rejection, FDA Updates for AZN, PFE

by Kinjel Shah

Glaxo (GSK) rejects a $68 billion buyout offer for its consumer healthcare unit from Unilever. FDA updates for Pfizer (PFE), AbbVie (ABBV) and AstraZeneca (AZN) grab headlines.

OPKO's (OPK) NGENLA Approved by Japan's MHLW for GHD Treatment

by Zacks Equity Research

Latest approval for OPKO's (OPK) NGENLA is expected to reduce the treatment frequency from daily injections, thereby better serving the GHD patient pool.

Best Growth Stocks to Buy for January 21st

by Zacks Equity Research

PFE, M, and ARCB made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 21, 2022

Sanofi (SNY) 2nd Dupixent Prurigo Nodularis Study Meets Goal (Revised)

by Zacks Equity Research

Sanofi's (SNY) PRIME is the second successful study on Dupixent for the prurigo nodularis indication.

Sanofi (SNY) 2nd Dupixent Prurigo Nodularis Study Meets Goal

by Zacks Equity Research

Sanofi's (SNY) PRIME is the second successful study on Dupixent for the prurigo nodularis indication.

Glaxo (GSK) Stock Down As Unilever Decides Not to Raise Offer

by Zacks Equity Research

Unilever decides that it will not raise its offer of $68 billion for Glaxo's (GSK) Consumer Healthcare business.

Valneva (VALN) Up as COVID-19 Jab Neutralizes Omicron Variant

by Zacks Equity Research

Three doses of Valneva's (VALN) inactivated COVID-19 vaccine candidate, VLA2001, neutralizes the Omicron variant of SARS-CoV-2, per data from preliminary lab studies. Shares rally.

Pfizer (PFE) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Pfizer (PFE) closed the most recent trading day at $53.54, moving -1.05% from the previous trading session.

Kinjel Shah headshot

Will 2022 Be a Better Year for Biotech Than 2021? 3 Big Picks

by Kinjel Shah

Regeneron (REGN), Vertex Pharmaceuticals (VRTX) and BioNTech (BNTX) are three large biotech stocks that are worth betting on in the current scenario.

Best Growth Stocks to Buy for January 19th

by Zacks Equity Research

PFE, M, and AN made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 19, 2022

Neena Mishra headshot

Why You Should Invest in Dividend Growth ETFs Now

by Neena Mishra

We highlight 3 ultra-cheap ETFs that focus on high quality dividend payers

Best Growth Stocks to Buy for January 18th

by Zacks Equity Research

BERY, M, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 18, 2022

Arena (ARNA) Stock Up in 6 Months on PFE Merger Deal & Pipeline

by Zacks Equity Research

Arena Pharmaceuticals' (ARNA) potential acquisition by Pfizer to enable it to advance the development of its pipeline, especially the company's lead candidate, etrasimod, for ulcerative colitis.

AstraZeneca (AZN) Enhertu sBLA Receives FDA Priority Tag

by Zacks Equity Research

AstraZeneca's (AZN) sBLA seeks approval of Enhertu for unresectable and/or metastatic HER2-positive metastatic breast cancer previously treated with an anti-HER2-based regimen.

Nalak Das headshot

5 Low-Beta High-Yielding Stocks to Buy in a Capricious Market

by Nalak Das

We have narrowed our search to five large-cap low-beta stocks with a solid dividend yield. These are: PFE, BAX, IBKR, PSA and CUBE.

Zacks Industry Outlook Highlights: Roche, Pfizer, AbbVie and Merck

by Zacks Equity Research

Roche, Pfizer, AbbVie and Merck are highlighted in this Industry Outlook article.

AbbVie's (ABBV) Rinvoq Gets FDA Nod for Atopic Dermatitis

by Zacks Equity Research

FDA approves AbbVie's (ABBV) Rinvoq for the treatment of moderate to severe atopic dermatitis in adults and children aged 12 and above. This is the third indication for Rinvoq in the United States.

Glaxo (GSK) Rejects Unilever's $68B Bid for Consumer Business

by Zacks Equity Research

Glaxo (GSK) rejects an offer from Unilever to acquire its consumer business worth 50 billion pounds ($68 billion). However, Unilever is likely to pursue the acquisition of the business.

Pfizer's (PFE) Cibinqo Gets FDA Nod for Atopic Dermatitis

by Zacks Equity Research

After a series of delays, Pfizer's (PFE) oral JAK inhibitor, Cibinqo (abrocitinib), gets approval for treating adults with atopic dermatitis in the United States.

Kinjel Shah headshot

4 Large-Cap Drugmaker Stocks to Watch Despite Omicron Woes

by Kinjel Shah

Drug/biotech and medical device companies are likely to remain in the spotlight in 2022. Among the large drugmakers Roche (RHHBY), Pfizer (PFE), AbbVie (ABBV), and Merck (MRK) are worth retaining in your portfolio.

The Zacks Analyst Blog Highlights: Pfizer (PFE), Beam Therapeutics, AbbVie, Merck and Glaxo

by Zacks Equity Research

Pfizer (PFE), Beam Therapeutics, AbbVie, Merck and Glaxo are highlighted in this analyst blog article.